Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : 2023 Biotech Charity Contest -- Ignore unavailable to you. Want to Upgrade?

To: technetium who wrote (93)	4/30/2023 7:29:52 PM
From: Aloner	Respond to of 233

Thank you for the corrected update, I appreciate all your time and effort once again. And I'm sure I speak for all the contestants. You wrote: " Let's see what the rest of the Year may bring"... My hope is: youtube.com

To: technetium who wrote (93)	5/3/2023 1:20:04 PM
From: Arthur Radley	Read Replies (2) \| Respond to of 233

My two “eye” portfolio stocks have shown stellar performances (EYEN) and (ISEE). Luckily I own both stocks in my personal stock account with a major overweight in Eyenova. They have a FDA decision happening next Tuesday.( ISEE )has nearly double YTD and this is because they are being purchased by Astellas(ALPMY) for $5.9 billion, or $40.00 per share. The deal is scheduled to be closed in the 3rd Q. For those who like short term profits with a spread for this buyout ($37.50 vs $40.00) this $2.50 is a nice profit.